araag2/HINT huggingface dataset:
Clinical trial NCT00297128 (phase 2, status: completed)
Conditions: rectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, cetuximab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age: 18-80

          -  bioptical confirmed adenocarcinoma of the rectum in operable T3-T4NxM0 status. In
             spite of infiltration of the neighbouring organs the tumor has to be basically
             surgically complete resectable

          -  no former chemotherapy, radiotherapy of pelvis or abdomen and/or tumor resection of a
             rectum carcinoma

          -  WHO performance status 0-2

          -  adequate bone marrow reserve (granulocytes - not more than 1.500/µl; thrombocytes -
             not more than 100.000/µl)

          -  adequate hepatic function ( bilirubin - not more than 1.5 x ULN; GOT and GPT - not
             more than 3.5 x ULN)

          -  adequate renal function (creatinin - not more than 1.5 mg/dl)

          -  women of childbearing potential: exclusion of pregnancy (negative urin or serum
             pregnancy test)

          -  willingness of women of childbearing potential and accordingly of potent men to use
             approved contraceptives (e.g. birth-control pill, loop, condom) during and at least 3
             month after conclusion of the study

          -  life expectancy of at least 3 month

          -  signed Informed Consent before recruitment

          -  exclusion of distant metastases at the time of recruitment

        Exclusion Criteria:

          -  former radiotherapy of pelvis or abdomen

          -  former chemotherapy

          -  any other kind of malign tumor (except adequate treated skin basalioma or in situ
             cervical carcinoma) in the last 5 years

          -  general contraindication or known hypersensitivity against Cetuximab and/or
             Capecitabine

          -  Non malign disease, if there is a contraindication with radiotherapy or chemotherapy
             with Cetuximab and Capecitabine or a resection of the rectum: high-graded cardiac
             insufficiency, angina pectoris, hypertension or arrhythmia, hepatic disease,
             significant neurological or psychiatric disorders

          -  florid, serious infections at the time of recruitment

          -  legally limited contractual capability or evidence of neurological or psychiatric
             disease, if it will constrict the patients compliance in the opinion of the
             investigator

          -  evidence of lacking cooperation of the patient

          -  pregnant or breast feeding women
Clinical trial NCT01541891 (phase 2, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: pro-148 ophthalmic solution, active comparator: systane ® ophthalmic solution
SMILES: CC(O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with diagnosis of mild-to-moderate drye eye syndrome.

          -  Male or female patients.

          -  Patients 18 years of age

        Exclusion Criteria:

          -  Patients with one blind eye.

          -  Visual acuity of 20/40 in any eye

          -  Patients with history of active stage of any other concomitant ocular disease.

          -  Patients taking any medication, topically or by any other route, which could interfere
             with the study's results, in the 3 days prior to trial or until a time period in which
             residual effects could be present.

          -  Contraindications or sensitivity to any component of the study treatments.

          -  Ocular surgery within the past 3 months.

          -  Contact lens users.

          -  Females of childbearing potential )may not participate in the study if any of the
             following conditions exist:

               -  They are pregnant,

               -  They are breastfeeding,

               -  They have a positive urine pregnancy test at screening,

               -  They intend to become pregnant during the study, or

               -  They do not agree to use adequate birth control methods for the duration of the
                  study.

          -  Participation in any studies of investigational drugs within 90 days previous to the
             inclusion.

        Discontinuation criteria:

          -  Patients could be discontinued before the completion of the study because of adverse
             events, pregnancy, protocol violations, lack of efficacy, or administrative reasons.
Clinical trial NCT00299390 (phase 2, status: terminated)
Conditions: small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: sagopilone (bay86-5302, zk 219477)
SMILES: C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1
Reason stopped: 
    since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop
    the trial due to lack of efficacy .
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven Small-cell lung cancer (SCLC)

          -  Stage of extensive disease defined by the presence of distant metastases

          -  At least 1 unidimensionally measureable lesion

          -  WHO performance status 0 to 1

          -  No previous SCLC-related chemotherapy

          -  No previous SCLC-related surgery

          -  No previous radiotherapy (excepting for brain metastasis)

          -  Adequate function of major organs and systems

               -  Nervous system

                    -  No Grade 2 or greater peripheral neuropathy

               -  Cardiovascular:

                    -  No symptomatic congestive heart failure

                    -  No unstable angina pectoris

                    -  No arrythmia needing continuous treatment

                    -  No other uncontrolled concurrent illness

        Exclusion Criteria:

          -  Superior vena cava syndrome or obstruction of any vital structure

          -  Untreated malignant hypercalcemia

          -  Pleural effusion as the only manifestation of disease

          -  Extensive disease amenable to radiation therapy

          -  Symptomatic brain metastases requiring whole brain irradiation

          -  Any concomitant malignancy excepting non-melanoma skin cancer or carcinoma in situ of
             the cervix
Clinical trial NCT00208767 (phase 2, status: completed)
Conditions: carotid artery diseases, atherosclerosis
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83
Drugs: valsartan, placebo
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  > 0.65 mm intima-media thickness of the carotid artery measured by ultrasound

          -  Males aged 21-80 years or women without child bearing potential up to age 80

          -  Can be on concomitant therapy with aspirin, thiazide diuretics, calcium antagonists
             (for treatment of hypertension), or beta-receptor antagonists.

          -  May be on statin if on stable dose for at least 2 months before recruitment

        Exclusion Criteria:

          -  Angiotensin-converting enzyme (ACE) inhibitor or ARB therapy in the previous 3 months.

          -  Initiation or change in dose of statin therapy within 2 months before the study

          -  Inability to return to Emory for follow-up blood drawing and MR imaging

          -  Age < 21 or > 80 years

          -  Premenopausal females with potential for pregnancy

          -  Current neoplasm

          -  Chronic renal failure [creatinine > 2.5 mg/dL]

          -  Diabetes with hemoglobin (Hb) A1c > 8.5

          -  Anticipated change in lipid lowering therapy

          -  Inability to give informed consent

          -  MR exclusion criteria

          -  Blood pressure > 140 mmHg systolic and > 90 mmHg diastolic

          -  Low-density lipoprotein (LDL) cholesterol level >130 mg/dl

          -  Acute coronary syndrome within 2 months

          -  Acute cerebrovascular accident within 2 months
Clinical trial NCT00057239 (phase 2, status: completed)
Conditions: major depressive disorder (mdd)
ICD codes: F25.1, F32.89, F33.8, F33.0, F33.1, F33.9, F32.0
Drugs: radafaxine
SMILES: C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Major Depressive Disorder (MDD)

          -  Duration of current depressive episode 12 weeks - 24 months

          -  Patients can read and write at a level sufficient to provide a signed consent

          -  If female, patients must be practicing an acceptable method of birth control

        Exclusion Criteria:

          -  Patients have other psychiatric disorders that would affect patient's response to
             treatment

          -  Patients have not responded to two or more adequate courses of antidepressant therapy

          -  Patients cannot be currently abusing illicit drugs or alcohol

          -  Patients are not currently receiving psychotherapy

          -  Patients have received electroconvulsive therapy within 6 months prior to screening

          -  Patients are pregnant or lactating
Clinical trial NCT00479752 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: folfox4 (oxaliplatin), cetuximab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  Male or female ≥ 18 years of age

          -  Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum

          -  Metastatic colorectal carcinoma not suitable for curative-intent resection-
             Availability of tumor sample (or able and willing to provide tumor sample) for EGFR
             assessment

          -  Presence of at least one lesion measurable unidimensionally by CT scan or MRI. (Target
             lesion(s) must not lie within an irradiated area)

          -  Karnofsky performance status of > 80 at study entry

          -  Leucocytes ≥ 3.0 x 10 9/L and neutrophils ≥1.5 x 10 9/L, platelets ≥ 100 x 10 9/L, and
             hemoglobin ≥ 9 g/dL.

          -  Bilirubin ≥ 1.5 x ULN

          -  ASAT and ALAT ≤ 2.5 x ULN (≤5 x ULN if liver metastasis are present)

          -  Serum creatinine ≤ 1.5 x ULN

        Exclusion Criteria:

          -  Brain metastasis (known or suspected)

          -  Previous chemotherapy for metastatic disease. Prior adjuvant chemotherapy is allowed
             if the chemotherapy treatment free interval is > 6 months.

          -  Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study
             entry

          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
             indicated in the study protocol

          -  Any investigational agent(s) within 4 weeks prior to entry

          -  Previous exposure to EGFR-pathway targeting therapy

          -  Clinically relevant coronary artery disease or a history of a myocardial infarction
             within the last 12 months

          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease

          -  Pre-existing neuropathy > grade 1. In case of prior oxaliplatin containing adjuvant
             chemotherapy: pre-existing neuropathy ≥ 1.

          -  Known grade 3 or 4 allergic reaction to any of the components of the treatment.

          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of
             the cervix. (Patients with a previous malignancy but without evidence of disease for ≥
             5 years will be allowed to enter the trial)

          -  Pregnancy or lactation

          -  Inadequate contraception (male or female patients) if of childbearing or procreational
             potential

          -  Known drug abuse/ alcohol abuse

          -  Legal incapacity or limited legal capacity

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or sign meaningful informed consent
Clinical trial NCT00584909 (phase 2, status: terminated)
Conditions: uterine cancer
ICD codes: C57.4, D28.2
Drugs: paclitaxel and carboplatin combination
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a elevated risk, surgical stage II, stage IC, grade 2 or 3
             adenocarcinoma of the endometrium.

          -  Patients must have undergone, a total abdominal hysterectomy, bilateral
             salpingo-oophorectomy, peritoneal washings, and a pelvic and para-aortic
             lymphadenectomy.

          -  Patients must have adequate organ function defined as:

               1. Platelets >/= 100,000/µ

               2. Granulocytes (ANC)>/= 1,500/µl

               3. Creatinine</= 1.6 mg/dl

               4. SGOT (AST) </= 3x upper limits of normal

               5. Bilirubin within institutional normal limits

          -  Patients must have adequate performance status (ECOG performance status 0-2 or
             Karnofsky Performance Status >40)

          -  Patients must be age 19 or greater and have signed informed consent.

        Exclusion Criteria:

          -  Patients with history of other malignancies within 5 years (except non- melanoma skin
             cancer or carcinoma-in-situ of the cervix) are ineligible.

          -  Patients with high-risk histologic subtypes of endometrial cancer such as papillary
             serous or clear cell histology are ineligible.

          -  Patients with histologic evidence of uterine sarcoma, including leiomyosarcoma,
             carcinosarcoma, endometrial stromal sarcoma, and adenosarcoma are ineligible.

          -  Patients who have received past pelvic radiotherapy are ineligible.

          -  Patients receiving any other investigational agents are ineligible.

          -  Patients with known hypersensitivity to paclitaxel and/or carboplatin are ineligible.
Clinical trial NCT00525915 (phase 2, status: completed)
Conditions: esophageal cancer, gastroesophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10, K22.6, K21.9, K21.00, K21.01
Drugs: 5-fluorouracil, oxaliplatin
SMILES: FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Local regional carcinoma of the thoracic esophagus (squamous cell or adeno) or
             gastroesophageal junction.

          2. Patients with T1N1, and T2-3 with any N (M1a only) will be eligible.

          3. Normal liver (serum glutamic-pyruvic transaminase (SGPT) < 56µL, Total Bilirubin <1.5
             mg/dL), kidney (Creatinine <1.75 mg/dL), and bone marrow functions (AGN >1,500µL,
             platelet count >100,000/µL).

          4. Performance status 0 or 1.

          5. Signed informed consent by the investigator or their designee and patient.

          6. Medically fit for surgery.

          7. No Celiac (except for the GE junction cancers), supraclavicular, or paraaortic nodal
             enlargement unless biopsy negative.

          8. None of the celiac nodes should be larger than 2 cm

          9. Male or Female but both sexes must practice adequate contraception while on therapy

         10. >/=18 years but less than 76 years

         11. No known allergy to any of the study drugs.

         12. No prior therapy for this cancer.

         13. No significant cancer (defined as non-melanomatous skin cancers and treated cervical
             cancers) within the past 5 years

         14. New York Heart Association (NYHA) I and II

        Exclusion Criteria:

          1. Patients with T1N0, T4, or M1b cancer will be excluded

          2. Significant comorbid conditions (defined as uncontrolled diabetes, active angina or
             heart failure, uncontrolled hypertension, or active psychiatric condition that
             prevents consistent participation and compliance).

          3. More than grade 1 neuropathy

          4. Unable to comprehend the requirements of the study or comply with it.
Clinical trial NCT00312819 (phase 2/phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: chemotherapy +/- disulfiram
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic non-small cell lung cancer

          -  Previously untreated

          -  ECOG performance status (PS) 0-1

          -  Liver function tests within the norm

        Exclusion Criteria:

          -  Over 18

          -  Willingness to abstain from alcohol

          -  Not pregnant

          -  Without a psychiatric history
Clinical trial NCT00368849 (phase 2, status: completed)
Conditions: huntington disease, chorea
ICD codes: G10, G25.5, G25.4, I02.0, I02.9
Drugs: atomoxetine, matching placebo
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed Huntington's disease (HD) diagnosis

          -  Age 18 to 65

          -  Must have mild HD

          -  Must have complaints of poor attention

        Exclusion Criteria:

          -  Childhood history of attention deficit hyperactivity disorder (ADHD) symptoms

          -  Diagnosis of schizophrenia, bipolar affective disorder, dementia, delirium or severe
             anxiety

          -  Current use of a monoamine oxidase inhibitor (MAOI) medication

          -  Pregnancy

          -  Uncontrolled hypertension

          -  Tachycardia

          -  Cardiovascular or cerebrovascular disease

          -  History of a loss of consciousness for greater than (or equal to) 5 minutes

          -  Having any neurological disorder or insult other than Huntington disease
Clinical trial NCT00660231 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bexarotene, gemcitabine hydrochloride
SMILES: CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed cutaneous T-cell lymphoma (CTCL) including its variants
             (e.g., mycosis fungoides and Sézary syndrome)

               -  CTCL stage IB, IIA, IIB, III or IVA disease

               -  No visceral involvement (i.e., stage IVB disease)

                    -  Lymphadenopathy is allowed

          -  Patients must have developed progressive disease after receiving or have been
             refractory to at least 1 course of prior standard, systemic, skin-directed therapy
             (e.g., interferon, chemotherapy, or denileukin diftitox [Ontak®])

          -  No CD30 + (Ki1+ve) anaplastic large cell lymphoma

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Life expectancy > 6 months

          -  Hemoglobin ≥ 9.0 g/dL (transfusions and/or erythropoietin are allowed)

          -  ANC > 1.5 x 10^9/L

          -  Platelet count ≥ 100 x 10^9/L

          -  Total bilirubin ≤ 1.25 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2 times ULN

          -  Serum creatinine ≤ 2 times ULN

          -  No clinically significant active infection

          -  No uncontrolled diabetes mellitus

          -  No excessive alcohol consumption

          -  No biliary tract disease

          -  No history of pancreatitis

          -  HIV negative

          -  Hepatitis B and C negative

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 1 month after study
             participation

          -  No other malignancy within the past 5 years except curatively treated basal or
             squamous cell skin cancer, cervical epithelial neoplasm CIN1, or carcinoma in situ

          -  No other significant medical or psychiatric condition that would preclude study
             compliance

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since any prior investigational agent

          -  More than 2 weeks since prior topical steroids or more than 4 weeks since prior
             systemic steroids

          -  Local radiotherapy may be given to isolated symptomatic tumour nodules that require
             immediate treatment for up to 2 weeks prior to study drugs

          -  No prior treatment with bexarotene (Targretin®)

          -  No concurrent anticancer therapy

          -  No concurrent investigational agent

          -  No concurrent drug therapy with other medications that can elevate triglycerides or
             cause pancreatic toxicity (e.g., gemfibrozil)

          -  No concurrent warfarin
Clinical trial NCT01432704 (phase 2/phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: colecalciferol
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Eligibility criteria:

        Inclusion Criteria:

          -  RRMS EDSS 0-5

          -  Betaferon used for at lest one month with positive MxA-response

        Exclusion Criteria:

          -  hypercalcaemia

          -  kidney stones

          -  uncontrolled hypertension

          -  hypothyreosis

          -  peanut allergy

          -  severe depression

          -  sarcoidosis

          -  use of other IMD than interferon-beta